ePrints

Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders

Lookup NU author(s): Professor Patrick Chinnery, Emeritus Professor Doug Turnbull

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Guidelines in the diagnosis and current dietary treatment of long-chain fatty acid (LCFA) defects have been collected according to evidence-based medicine. Since the identification of carnitine and carnitine palmitoyltransferase deficiency more than 25 years ago, nearly every enzymatic step required for β-oxidation has been associated with an inherited metabolic disorder. These disorders effectively preclude the use of body fat as an energy source. Clinical consequences can range from no symptoms to severe manifestations including cardiomyopathy, hypoglycaemia, peripheral neuropathy and sudden death. A diet high in carbohydrates, diet with medium-chain triglycerides and reduced amount of LCFA has a beneficial effect (class IV evidence) and in appropriate deficiency states carnitine and riboflavin are used (good practice points). © 2006 EFNS.

Publication metadata

Author(s): Angelini C, Federico A, Reichmann H, Lombes A, Chinnery P, Turnbull D

Publication type: Article

Publication status: Published

Journal: European Journal of Neurology

Year: 2006

Volume: 13

Issue: 9

Pages: 923-929

ISSN (print): 1351-5101

ISSN (electronic): 1468-1331

Publisher: Wiley-Blackwell

URL: http://dx.doi.org/10.1111/j.1468-1331.2006.01482.x

DOI: 10.1111/j.1468-1331.2006.01482.x

PubMed id: 16930355

Altmetrics

Share